Form 4: Cryoport Director Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Cryoport director Ramkumar Mandalam exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- On December 2, 2024, Cryoport director Ramkumar Mandalam exercised 10,834 stock options at a price of $4.80 per share.
- Concurrently, Mandalam sold 7,369 shares of common stock at a weighted average price of $7.4607 per share.
- The sale of shares was executed under a pre-arranged 10b5-1 trading plan adopted on March 15, 2024.
- The proceeds from the sale were used to cover the exercise price of the options and associated withholding taxes.
- Following these transactions, Mandalam directly owns 59,497 shares of Cryoport common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing a stock option exercise and share sale by a director under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine filing related to insider trading activity and is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives and directors of publicly traded companies, such as those in the biotechnology and pharmaceutical sectors, to manage their personal finances while avoiding potential insider trading issues.
- Similar filings are regularly seen from companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies, which also have executives and directors who utilize these plans.
- The price range of the stock sale ($7.10 to $7.81) is typical for transactions of this nature, reflecting the market price at the time of the sale.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not reflect a change in the director's long-term view of the company.
Key Dates
| Date | Description |
|---|---|
| 01/18/2015 | Start date for the vesting of the stock options, which vested ratably over 48 months on the 18th of each month. |
| 03/15/2024 | Date the 10b5-1 trading plan was adopted by the reporting person. |
| 12/02/2024 | Date of the stock option exercise and share sale. |
| 12/04/2024 | Date the Form 4 was signed. |
| 12/18/2024 | Expiration date of the stock options. |
Keywords
Cryoport, stock options, insider trading, Form 4, 10b5-1 plan, share sale, Ramkumar Mandalam, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.